[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
[ Thu, Aug 25th 2022 ]: WOPRAI
Dae Gon Ha Upgraded (VERV) to Strong Buy and Increased Target to $56 on, Aug 25th, 2022
- 🞛 This publication is a summary or evaluation of another publication
- 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Dae Gon Ha of Stifel, Upgraded "Verve Therapeutics, Inc." (VERV) to Strong Buy and Increased Target from $32 to $56 on, Aug 25th, 2022.
Dae has made no other calls on VERV in the last 4 months.
There is 1 other peer that has a rating on VERV. Out of the 1 peers that are also analyzing VERV, 0 agree with Dae's Rating of Hold.
This is the rating of the analyst that currently disagrees with Dae
- Kostas Biliouris of "BMO Capital" Maintained at Buy with Increased Target to $62 on, Monday, July 18th, 2022